Table 1. Clinical, histological and chromosome status data for the retrospective and prospective series.
| Number | Mean Age | Sex | Histology | Site | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Retrospective | (%) | (range) | M | F | OII | OIII | OAII | OAIII | GBMO | F | T | Other |
| Codeletion | 20 (37) | 45 (26–63) | 12 | 8 | 7 | 9 | 2 | 2 | 0 | 16 | 3 | 1 |
| Deletion 1p | 3 (6) | 76 (74–79) | 2 | 1 | 0 | 3 | 0 | 0 | 0 | 1 | 1 | 1 |
| Deletion 19q | 3 (6) | 59 (54–62) | 1 | 2 | 0 | 1 | 0 | 1 | 1 | 1 | 2 | 0 |
| Normal | 8 (15) | 50 (25–82) | 3 | 5 | 0 | 3 | 3 | 1 | 1 | 5 | 2 | 1 |
| Imbalance | 19 (36) | 48 (23–76) | 11 | 8 | 4 | 3 | 8 | 3 | 1 | 7 | 7 | 5 |
| Total (%) | 53 | 50 | 29 (55) | 24 (45) | 11 (20) | 19 (36) | 13 (25) | 7 (13) | 3 (6) | 30 (57) | 15 (28) | 8 (15) |
| Prospective | ||||||||||||
| Codeletion | 19 (42) | 52 (26–77) | 7 | 12 | 5 | 8 | 2 | 3 | 1 | 14 | 3 | 2 |
| Deletion 1p | 2 (4) | 51 (42–60) | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 |
| Deletion 19q | 2 (4) | 40 (28–52) | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 |
| Normal | 5 (12) | 52 (25–86) | 2 | 3 | 0 | 0 | 4 | 1 | 0 | 1 | 2 | 2 |
| Imbalance | 17 (38) | 44 (24–63) | 6 | 11 | 0 | 3 | 8 | 6 | 0 | 11 | 2 | 4 |
| Total (%) | 45 | 48 | 18 (40) | 27 (60) | 7 (16) | 11 (24) | 15 (34) | 11 (24) | 1 (2) | 27 (60) | 9 (20) | 9 (20) |
OII: WHO grade II oligodendroglioma, OIII: anaplastic oligodendroglioma
OAII: grade II oligoastrocytoma, OAIII: anaplastic oligoastrocytoma
GBMO: glioblastoma with oligodendroglial component, F: frontal, T: temporal.